Diagnostica precoce



Calculate your BMI
(Body Mass Index)

BMI Categories:
Underweight = <18.5
Normal weight = 18.5-24.9
Overweight = 25-29.9
Obesity = BMI of 30 or greater

Your Height: cm
Your Weight: kg
Your BMI:


Diagnosis and treatment of disease in its early stages is often the key to success.

The 21th century saw impressive applications of engineering technology in diagnosis, as well as the application of such technology in other fields of medicine.

Electrocardiogram (testing heart function); electroencephalogram (brain); electroretinography and related techniques (vision) may be briefly mentioned. And in the category of imaging: the "classical" X-ray and its 3-dimensional development, computer tomography (CT); ultrasonic echography

Such advances continue, particularly in making such high-tech diagnostic methods more "accessible"; but more recently the most striking progress has been in biochemical detection methods. These have a long history, but have recently advanced rapidly, with the development of highly selective and specific biochemical tests which are easy to use -- sometimes so easy that they have moved out of the laboratory altogether. These have great potential in mass-screening tests; but here the problems tend to be not so much technical, but more organisational and economic.

antiaging, computer tomography, ultrasonic, echography, diagnosis, diagnostic, ct, psa.


Proteins in Lung Cancer Cells That May Provide Potential Drug Targets Identified

ScienceDaily (Nov. 26, 2009) — Researchers from Boston University School of Medicine (BUSM) and the Boston University Biomedical Engineering Department have identified a number of proteins whose activation allows them to distinguish between cancer and normal cells with almost 97 percent accuracy. In addition, the BU researchers have developed a new computational strategy to analyze this data and specifically identify key biological pathways (molecular circuits) that are active in cancer and "dormant" in normal cells.

The study which appears in the November 25th issue of PLoS One, should ultimately lead to the development of drugs specifically aimed to inhibit these proteins.

According to the BU researchers, there are many features that make cancer cells different from normal cells. They look different histologically, they proliferate and divide at different rates, they are immortal unlike normal cells, and are less communicative with their neighbor cells. They are also more "selfish" in refusing to commit suicide (programmed cell death) which normal cells do when their genomes become unstable.

Much of the cellular machinery involved with these biological processes is controlled by a command control and communication system called signal transduction. Signal transduction is in large part controlled by a process called phosphorylation. When a protein is phosphorylated it either becomes active or repressed depending on its special function. "Therefore, identifying the phosphorylation status of proteins in cancer cells versus normal cells provides us with a unique ability to understand and perhaps intervene with the command and control center of cancer cells," said co-senior author Simon Kasif, PhD, who is the co-director of the Center of Advanced Genomic Technology and a professor in the department of biomedical engineering at BU. "Drugs are most effective on cancers when they attack the proteins that are activated," he added.

While cancers are highly heterogeous in their make-up, the BU researchers believe that a drug that would target this collection of proteins would be effective treatment for most lung cancers.

"This is the first statistically validated phosphopeptide signature to diagnose any disease, much less cancer or lung cancer," explained senior co-author Martin Steffen, MD, PhD, an assistant professor of pathology and laboratory medicine at BUSM, and director, Proteomics Core Facility at BUSM.

This research was performed in collaboration with Cell Signaling Technology employing their Phosphoscan "test kit".

A follow-up study is currently underway at BU to identify which cancers respond or not respond to existing cancer drugs based on the results of this test.

Funding for this study was provided by the National Human Genome Research Institute and the American Lung Association.

en de it ru fr sp +39-3285543565

eXTReMe Tracker

More information about Fasting&Cleansing program read here

© 1991-2019 Anti-Aging Corp., All rights reserved. Condizioni / Mappa del sito / Contatti / Affiliazione